NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by $0.08. The biotechnology company earned $2.98 million during the quarter, compared to analysts' expectations of $4.33 million. Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%. View Five Prime Therapeutics' Earnings History.

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Five Prime Therapeutics.

4 brokers have issued 1-year price objectives for Five Prime Therapeutics' stock. Their forecasts range from $10.00 to $24.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 163.3% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Five Prime Therapeutics.

News stories about FPRX stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Five Prime Therapeutics.

Some companies that are related to Five Prime Therapeutics include Aprea Therapeutics (APRE), Dova Pharmaceuticals (DOVA), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), Vanda Pharmaceuticals (VNDA), Eagle Pharmaceuticals (EGRX), CannTrust (CNTTF), Provention Bio (PRVB), ANI Pharmaceuticals (ANIP), Emisphere Technologies (EMIS), Retrophin (RTRX), Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), Akero Therapeutics (AKRO) and Collegium Pharmaceutical (COLL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Opko Health (OPK), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD) and Inovio Pharmaceuticals (INO).

Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.76%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $5.57.

Five Prime Therapeutics has a market capitalization of $202.69 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]